Physician profile
Christopher Amato
NPI 1639251903
$33,880.92
in general payments reported to CMS, 2019-2025
22 companies · $32K in 2025
The $32K reported for 2025 was more than what 99% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108 · 2020: $188 · 2021: $335 · 2022: $284 · 2023: $416 · 2024: $226 · 2025: $32K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $23K · Consulting Fee: $4,241 · Honoraria: $3,500 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,344 · Food and Beverage: $824.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $23,056.80 |
| Consulting Fee | $4,240.98 |
| Honoraria | $3,500.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,344.38 |
| Food and Beverage | $823.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aero US INC | $32,142.16 | 2025 | Aerogen Solo Nebulizer System, Aerogen Usb Controller System, Aerogen Solo; Aerogen Ultra |
| Pfizer INC. | $311.77 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $220.93 | 2019-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Kaleo, INC. | $209.63 | 2019-2023 | Auvi-Q |
| Sanofi Pasteur INC. | $184.50 | 2020-2024 | |
| Glaxosmithkline, LLC. | $145.04 | 2019-2023 | Bexsero |
| Tris Pharma INC | $137.48 | 2019-2022 | |
| Cranial Technologies, INC | $119.79 | 2020-2025 | Doc Band |
| Takeda Pharmaceuticals U.S.A., INC. | $79.72 | 2020-2022 | |
| Ironshore Pharmaceuticals INC. | $59.00 | 2021-2024 | |
| Seqirus USA INC | $48.21 | 2022-2025 | Flucelvax, Fluad |
| Ars Pharmaceuticals Operations, INC. | $41.28 | 2025 | Neffy |
| Sobi, INC | $25.89 | 2019 | |
| Sanofi-Aventis U.S. LLC | $24.74 | 2025 | |
| Hologic Sales and Service, LLC | $22.60 | 2023 | Thinprep 2000 Processor |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $21.47 | 2021 | |
| Corium, LLC | $17.14 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.78 | 2025 | Zoryve |
| Pharming Healthcare, INC. | $14.92 | 2022 | |
| Organon LLC | $13.83 | 2025 | |
| Neos Therapeutics, Lp | $12.84 | 2020 | |
| Genentech USA, INC. | $12.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Amato listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.